Hank Safferstein
Directeur Général chez Generian Pharmaceuticals, Inc.
Profil
Hank Safferstein, PhD, JD, MBA, currently serves as a Senior Advisor, UPMC Enterprises and CEO, Generian, a UPMC portfolio company.
He is Board Director of Ariel Precision Medicine.
Previously, he was Senior Vice President of Cognition Therapeutics, a clinical stage, small molecule, Alzheimer’s disease company and Adjunct Professor at Carnegie Mellon University.
He was Founder and CEO of Cognition Therapeutics and Complexa, Inc., a clinical stage biotechnology company focused on fibrosis and inflammation for orphan disease indications.
Dr. Safferstein served as Vice President, Business Development, for Omrix Biopharmaceuticals, a commercial-stage company that develops and markets biosurgical and passive immunotherapy products (acquired by J&J) and was Vice President, Business Development for Acorda Therapeutics, a central nervous system drug development and marketing company.
Prior to joining Acorda Therapeutics, Dr. Safferstein served in various business development and marketing positions with Bristol-Myers Squibb.
From 1991-1997, he was Director, Technology Transfer at the National Heart, Lung and Blood Institute and Cooperative Venture Manager for the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Dr. Safferstein was an NIH Post-Doctoral Fellow and Fellow of the Multiple Sclerosis Society.
Dr. Safferstein received a BA in Biochemistry from Rutgers University, a PhD in Human Anatomy and Neurobiology from the University of Louisville, a JD from the American University, Washington College of Law and an MBA from Columbia University.
He is an active member of the Maryland Bar.
Postes actifs de Hank Safferstein
| Sociétés | Poste | Début |
|---|---|---|
PLSG Capital Investment Programs
 PLSG Capital Investment Programs Investment ManagersFinance Founded in 2002, PLSG Capital Investment Programs is a venture capital/private equity firm located in Pittsburgh, Pennsylvania. | Corporate Officer/Principal | - |
Generian Pharmaceuticals, Inc.
 Generian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Generian Pharmaceuticals, Inc. provides pharmaceutical services. The company is headquartered in Pittsburgh, PA. | Directeur Général | - |
UPMC Enterprises
 UPMC Enterprises Investment ManagersFinance UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania. | Consultant / Advisor | 01/01/2018 |
Ariel Precision Medicine, Inc.
 Ariel Precision Medicine, Inc. Medical/Nursing ServicesHealth Services Ariel Precision Medicine, Inc. provides integrated genomics and digital health services. It offers precision medicine solutions for the diagnosis, monitoring, and treatment of complex chronic diseases and disorders. The company was founded by David Whitcomb and Jessica M. Gibson and is headquartered in Pittsburgh, PA. | Directeur/Membre du Conseil | 01/03/2017 |
Anciens postes connus de Hank Safferstein
| Sociétés | Poste | Fin |
|---|---|---|
| COGNITION THERAPEUTICS, INC. | Directeur Général | 28/10/2016 |
OMRIX Biopharmaceuticals, Inc.
 OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Corporate Officer/Principal | 31/05/2007 |
| ACORDA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2005 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 31/12/1999 |
| National Heart, Lung & Blood Institute | Corporate Officer/Principal | 01/01/1997 |
Formation de Hank Safferstein
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Rutgers State University of New Jersey | Undergraduate Degree |
| University of Louisville | Doctorate Degree |
| American University Washington College of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| COGNITION THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
OMRIX Biopharmaceuticals, Inc.
OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Health Technology |
Brainstage, Inc.
 Brainstage, Inc. Miscellaneous Commercial ServicesCommercial Services Brainstage, Inc. provides technologies for healthcare and drug development. It acquires, develops, aggregates, and commercializes technologies within the healthcare field. The company was founded by Anthony A. Florence Jr. and Donald Doherty in 2007 and is headquartered in Carnegie, PA. | Commercial Services |
Multiple Sclerosis Society
 Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Commercial Services |
TransPharma Medical Ltd.
 TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
Pittsburgh Life Sciences Green House
 Pittsburgh Life Sciences Green House Investment ManagersFinance Pittsburgh Life Sciences Green House (PLSG) is a venture capital firm founded in 2002. The firm is headquartered in Pittsburgh, Pennsylvania. | Finance |
PLSG Capital Investment Programs
PLSG Capital Investment Programs Investment ManagersFinance Founded in 2002, PLSG Capital Investment Programs is a venture capital/private equity firm located in Pittsburgh, Pennsylvania. | Finance |
| National Institute of Allergy & Infectious Diseases | Government |
| National Heart, Lung & Blood Institute | Government |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Health Technology |
Ariel Precision Medicine, Inc.
Ariel Precision Medicine, Inc. Medical/Nursing ServicesHealth Services Ariel Precision Medicine, Inc. provides integrated genomics and digital health services. It offers precision medicine solutions for the diagnosis, monitoring, and treatment of complex chronic diseases and disorders. The company was founded by David Whitcomb and Jessica M. Gibson and is headquartered in Pittsburgh, PA. | Health Services |
UPMC Enterprises
UPMC Enterprises Investment ManagersFinance UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania. | Finance |
Generian Pharmaceuticals, Inc.
Generian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Generian Pharmaceuticals, Inc. provides pharmaceutical services. The company is headquartered in Pittsburgh, PA. | Health Technology |
